Biologic therapies | Total no of patients treateda | No of TB episodes b (% of TB episodes/ total treated) c | Time to TB (months) d Median (IQR) | |
---|---|---|---|---|
All biologics | – | 41 | 8.30 (3.67–27.70) | |
TNF-α inhibitors | 209 | 20 | 18.95 (5.08–32.79) | |
adalimumab | 48 | 4 (8.3%) | 12.56 (3.20–18.90) | |
etanercept | 49 | 3 (6.1%) | 33.84 (12.59–46.82) | |
golimumab | 12 | 2 (16.7%) | 4.82 (4.33–5.31) | |
infliximab | 100 | 11 (11.0%) | 27.70 (3.64–39.02) | |
Non-TNF-α inhibitors | 441 | 21 | 7.43 (2.83–16.24) | |
abatacept | 4 | 0 | – | |
rituximab | 418 | 20 (4.8%) | 7.08 (2.48–18.02) | |
tocilizumab | 18 | 1 (5.6%) | 15.02 (15.02–15.02) | |
ustekinumab | 1 | 0 | – |